The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Belantamab mafodotin induces immunogenic cell death within 24-hrs of administration in NDMM
Ioannis Ntanasis-Stathopoulos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the results of a study investigating the use of belantamab mafodotin in combination with lenalidomide and dexamethasone (Rd) in the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
